Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Trial Profile

A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms KALESOLO
  • Most Recent Events

    • 26 Jul 2017 Results (n=637) of pooled analysis of NCT00140751, NCT00421551, NCT00946595 trials analysing distribution of ultrasensitive viral load (USVL) and impact of USVL on virological failure presented at the 9th International AIDS Society Conference on HIV Science
    • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Results have been published in the Journal of Antimicrobial Chemotherapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top